Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Phase IB Study of GDC-6036 in Combination with Cetuximab in Patients With Colorectal Cancer (CRC) With KRAS G12C Mutation

April 28th 2023

Jayesh Desai, MBBS, FRACP, shares data from a phase IB study investigating KRAS G12C inhibitor GDC-6036, or divarasib, in combination with cetuximab for the treatment of patients with colorectal cancer.

Real-World Use of HER2-Directed Therapies in Colorectal Cancers

April 28th 2023

Expert perspectives on the real-world use of HER2-directed therapies in patients with HER2-amplified colorectal cancer.

Tucatinib/Trastuzumab Approval Highlights Expansion of Tailored Therapies in HER2+ CRC

April 21st 2023

John L. Hays, MD, PhD, discusses the importance of tailoring therapies for patients with CRC who express HER2 or have other actionable targets, the need to develop optimal sequences for local and systemic therapy in CRC, and key updates in hepatocellular carcinoma and pancreatic cancer.

HER2-Amplified Colorectal Cancer: Clinical Trial Data

April 21st 2023

A focused discussion on HER2-amplified colorectal cancer and respective clinical trials that inform use of targeted agents in this setting.

Treatment Algorithm for Metastatic Colorectal Cancer

April 21st 2023

Broadening their conversation, expert oncologists define the treatment algorithm for patients diagnosed with colorectal cancer.

FDA Grants Fast Track Designation to Botensilimab Plus Balstilimab in Non–MSI-H/dMMR mCRC

April 20th 2023

The FDA has granted a fast track designation to the combination of botensilimab plus balstilimab for the treatment of patients with non–microsatellite instability–high/mismatch repair–deficient metastatic colorectal cancer with no active liver involvement.

Novel Detection Methods May End Chemotherapy for Patients With CRC

April 19th 2023

A new genetic test that may allow patients with colorectal cancer to avoid chemotherapy after tumor resection is under investigation at AdventHealth Cancer Institute in Orlando, Florida.

FDA Grants Priority Review to TAS-102 Plus Bevacizumab for Refractory mCRC

April 18th 2023

The FDA has accepted for priority review the supplemental new drug application seeking the approval of trifluridine/tipiracil as a single agent or in combination with bevacizumab for use in select patients with refractory, metastatic colorectal cancer.

Divarasib Plus Cetuximab Demonstrates Promising Clinical Activity and Manageable Safety in KRAS G12C–Mutant CRC

April 18th 2023

The selective, oral KRASG12C inhibitor divarasib demonstrated promising clinical activity in patients with colorectal cancer treated with the agent plus cetuximab.

African Ancestry Is Associated With Fewer Actionable Alterations in CRC

April 17th 2023

Patients with African ancestry with colorectal cancer have fewer actionable gene mutations than those with European ancestry, leading to fewer targeted treatment options in this population.

MOUNTAINEER and DESTINY-CRC01 Trials Expand Second-Line Options for HER2+ mCRC

April 15th 2023

Alaa Muslimani, MD, discusses the significance of the phase 2 DESTINY-CRC01 and MOUNTAINEER-03 trials on HER2-positive metastatic colorectal cancer treatment in the second line, efforts to expand the use of these agents in earlier disease settings, and the need for more robust clinical data and larger investigations for this population.

Role of Circulating Tumor DNA Testing in Colorectal Cancer

April 14th 2023

In the context of colorectal cancer clinical trials, panelists reflect on the role of liquid biopsies to help inform treatment decisionmaking.

Role of HER2 Expression in Colorectal Cancer

April 14th 2023

A brief review of HER2 amplification and how it may impact the treatment pathway for patients with a diagnosis of colorectal cancer.

Actionable Subsets of Patients With CRC Drive Progress

April 12th 2023

With an overall 5-year survival rate of under 15% in patients with metastatic colorectal cancer, investigators have sought to parse mutational analyses to increase gains.

Dr Foote on the Use of Tucatinib Plus Trastuzumab in HER2-Amplified mCRC

April 10th 2023

Micheal Foote, MD, discusses the use of tucatinib plus trastuzumab compared with chemotherapy in the management of HER2-amplified metastatic colorectal cancer.

Low RNA Expression of RAD51, BRCA1 Associated With Prolonged OS in HRP CRC

April 8th 2023

Daniel Walden, MD, discusses the goal of analyzing RNA expression of wild-type HR genes in CRC, the importance of evaluating the benefit of chemotherapeutic approaches in patients with HRP CRC based on RNA expression levels, and the next steps for validating and implementing these findings in clinical practice.

Pembrolizumab/Lenvatinib Combo Misses OS End Points in Select Advanced Melanoma and mCRC

April 7th 2023

The phase 3 LEAP-003 and LEAP-017 trials evaluating pembrolizumab plus lenvatinib did not meet their primary end points of overall survival in select patients with unresectable or metastatic melanoma and metastatic colorectal cancer, respectively.

Immunotherapy in Metastatic Colorectal Cancer: More Than Just MSI-H?

April 7th 2023

In an era of genomics, proteomics, and immunology a biomarker as simple as anatomy may be useful in terms of predicting responses in patients with colorectal cancer.

Colorectal Cancer: An Overview on Molecular Profiling

April 7th 2023

Shared insight on appropriate molecular lab testing options that should be explored following a diagnosis of colorectal cancer.

Colorectal Cancer: Prevalence, Workup, and Molecular Subtypes

April 7th 2023

Opening their discussion on colorectal cancer, expert panelists consider its growing prevalence and highlight key molecular subtypes.